What is the fair value of OMER stock?

Our analysis estimates the fair value range for OMER to be between $9.57 and $13.66. The current price is $17.19.

What is the analyst price target for OMER?

The average Wall Street analyst price target for OMER is $33.00. This implies a potential upside of 92.0% from current levels.

OMER Stock Analysis: Buy, Sell, or Hold?

OMER - Omeros Corporation

PHARMACEUTICAL PREPARATIONS

$17.19

-0.16 (-0.92%) ▼

5d: +29.74%

30d: +86.44%

90d: +29.44%

WAIT

LOW Confidence

Protect Your OMER Gains

Analysis Updated: Aug 14, 2026 12:00 AM ET

Earnings: Aug 13, 2026 0d

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Aug 11, 2026 at $13.60 · last confirmed Aug 13, 2026

Strength: 7.9/10

Get Alerted When OMER Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OMER is 25.8% above its trading range ($13.66). Market expects -15.5% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 10.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$13.31

Based on 7.0% avg growth

INTRINSIC VALUE TODAY

$8.27

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: OMER is currently trading at $17.19, which is considered extended relative to its 30-day fair value range of $9.57 to $13.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 45.2) compared to its historical average (74.9). Remarkably, the market is currently pricing in an annual earnings decline of 15.5% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, OMER is in a strong uptrend. Immediate support is located at $11.90, while resistance sits at $18.14.

Market Sentiment: OMER scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.00 (+92.0%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $9.57 - $13.66

Company Quality Score 44/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 19.0%

Protect Your Profits

OMER is technically overbought (RSI 82). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

BEARISH: Price significantly overextended (+25.8% above its trading range)
BEARISH: Weak technical setup (15/100)
BULLISH: High volume confirmation
BULLISH: Trading 92.0% below Wall St target ($33.00)
WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $9.57 - $13.66

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $11.90

Resistance Level $18.14

Current Trend Strong Uptrend

Technical data as of Aug 14, 2026

Fundamental Context

Forward P/E (Next Year Est.) 45.24

Wall Street Target $33.00 (+92.0%)

Revenue Growth (YoY) 14.9%

Profit Margin 871.0%

Valuation Discount vs History -15.5% cheaper

PE vs Historical 45.2 vs 74.9 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -15.5% (market-implied from PE analysis)

1-Year Target $15.47 (-10%)

2-Year Target $13.92 (-19%)

3-Year Target $12.53 (-27%)

3-Yr Target (if PE normalizes) (PE: 45→75) $20.75 (+21%)

📈 Valuation based on Current Earnings

Trailing PE: 12.05 | Current EPS (TTM): $1.44

Bull Case $9.54 (-45%)

Analyst growth -50.0%, PE expands to 13.3

Base Case $8.67 (-50%)

Market implied -50.0%, PE stable at 12.1

Bear Case $11.80 (-31%)

Severe decline -20.0%, PE contracts to 10.2

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 45.2 to 74.9

Stabilization Target: $28.46 (+65.6%)

PE Expansion Potential: +65.6%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 16, 2026 2:22 AM ET
Data refreshes hourly during market hours. Next update: 3:22 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is OMER showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for OMER.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
NTLA Intellia Therapeutics Inc	STRONG BUY 29 analysts	$26	43 HOLD
MLTX MoonLake Immunotherapeut…	STRONG BUY 16 analysts	$28	60 BUY
REGN Regeneron Pharmaceutical…	STRONG BUY 25 analysts	$834	34 SELL
JAZZ Jazz Pharmaceuticals PLC	STRONG BUY 18 analysts	$281	53 HOLD
TNYA Tenaya Therapeutics Inc	STRONG BUY 9 analysts	$3	70 BUY

NTLA Intellia Therapeu…

43 HOLD

MLTX MoonLake Immunoth…

60 BUY

REGN Regeneron Pharmac…

34 SELL

JAZZ Jazz Pharmaceutic…

53 HOLD

TNYA Tenaya Therapeuti…

70 BUY

Advanced OMER Option Strategies

Professional options setups generated by AI based on today's OMER price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for OMER

OMER Technical Chart OMER Price Prediction OMER Earnings Date OMER Investment Advisor OMER Fair Price Analyzer OMER Options Advisor OMER Options Chain OMER Options Analysis OMER Competitors

Compare OMER with Peers

OMER vs OCUL
Which one to buy?

OMER vs KPTI
Which one to buy?

OMER vs PTCT
Which one to buy?

OMER vs MGNX
Which one to buy?

OMER vs VNDA
Which one to buy?

IMRX vs OMER
Winner: OMER

NXTC vs OMER
Winner: Tie

AGEN vs OMER

SRZN vs OMER

SLGL vs OMER
Winner: Tie

ABL vs OMER

OMER vs DNA
Winner: Tie

OMER vs TBPH

OMER vs GYRE
Winner: OMER

OABI vs OMER

Create New Comparison View All Competitors

Tradestie